We hope that in this era of immunotherapy, this information on HLA polymorphisms in GBM patients may provide insight into immunotherapies focusing on TCR-peptide/MHC interactions such as peptide vaccines, neoantigen vaccines, and TCR-engineered T cell therapy. The gene discussed is HLA-C; the disease is glioblastoma.